A modelled analysis of the impact of COVID-19-related disruptions to HPV vaccination
eLife · 13.10.2023 · 12
DOI: 10.7554/elife.85720 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, online erschienen am 13.10.2023. Verfasst von Louiza S Velentzis und 5 weiteren Autor:innen. Beteiligte Einrichtung: Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Papillomavirus Infections, COVID-19, Papillomavirus Vaccines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Cancer Institute New South Wales.
Abstract (Originalsprache)
COVID-19 disrupted school attendance in many countries, delaying routine adolescent vaccination against human papillomavirus (HPV) in some settings. We used Policy1-Cervix , a dynamic model simulating HPV transmission, natural history, vaccination, cervical screening, and diagnosis of HPV-related cancers, to estimate the impact on HPV-related cancers from disruptions to HPV vaccination in a high-income setting. A baseline scenario of no disruption to HPV vaccination was modelled, which assumed uptake of the nonavalent vaccine at the age of 12 by 82.4% of females and 75.5% of males, as is the coverage in Australia. Additional lifetime HPV-related cancer cases were calculated for three disruption scenarios affecting one birth cohort (2008; aged 12 in 2020) compared to the baseline scenario: (1) 1-year delay (no doses missed); (2) 1- to 7-year delay (slow catch-up); (3) no catch-up (herd effects only). A fourth scenario assumed no catch-up HPV vaccination for two birth cohorts, that is all individuals born in 2008 and in 2009 missed vaccination (worst-case scenario). Compared to 1532 HPV-related cancer cases estimated for the baseline no disruption scenario, we found a 1-year delay could result in ≤0.3% more HPV-related cancers ( n = 4) but the increase would be greater if catch-up was slower (5%; n = 70), and especially if there was no catch-up (49%; n = 750). Additional cancers for a single missed cohort were most commonly cervical (23% of the additional cases) and anal cancers (16%) in females and oropharyngeal cancers in males (20%). In the worst-case scenario of two birth cohorts missing vaccination, ≤62% more HPV-related cancers would be diagnosed ( n = 1892). In conclusion, providing catch-up of missed HPV vaccines is conducted, short-term delays in vaccinating adolescents are unlikely to have substantial long-term effects on cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia.
- School of Population and Global Health, University of Melbourne, Victoria, Australia.
- Australian Centre for Prevention of Cervical Cancer, Victoria, Australia.
- The Kirby Institute, University of New South Wales, Sydney, Australia.
ORCID-Profile: Louiza S Velentzis, Megan A Smith
Förderung
- National Health and Medical Research Council
- Cancer Institute New South Wales
Zitieren
APA
Velentzis, L. S., Smith, M. A., Killen, J., Brotherton, J. M. L., Guy, R., & Canfell, K. (2023). A modelled analysis of the impact of COVID-19-related disruptions to HPV vaccination. eLife, 12. https://doi.org/10.7554/elife.85720
Vancouver
Velentzis LS, Smith MA, Killen J, Brotherton JML, Guy R, Canfell K. A modelled analysis of the impact of COVID-19-related disruptions to HPV vaccination. eLife. 2023;12. doi:10.7554/elife.85720
BibTeX
@article{Velentzis2023,
author = {Velentzis, Louiza S and Smith, Megan A and Killen, James and Brotherton, Julia M L and Guy, Rebecca and Canfell, Karen},
title = {A modelled analysis of the impact of COVID-19-related disruptions to HPV vaccination},
journal = {eLife},
year = {2023},
volume = {12},
doi = {10.7554/elife.85720}
}
EUVIMED